Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Myelofibrosis

Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Myeloproliferative neoplasms is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. The genes most frequently associated with MF are Janus kinase 2 gene (JAK2) and calreticulin gene (CALR).

Epidemiology- According to Thelansis, it is estimated that the annual incidence in the United States population is 1.5 cases per 100,000 persons in the United States.

Competitive landscape of Myelofibrosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Myelofibrosis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Myelofibrosis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        PXS-5505        Pharmaxis        Phase 2

2        KRT-232        Kartos Therapeutics, Inc.        Phase 2

3        Ruxolitinib        Incyte Corporation        Phase 1

4        Selinexor        Karyopharm Therapeutics Inc        Phase 2

5        Ruxolitinib        Novartis Pharmaceuticals        Phase 2

6        SAR302503 (TG101348)        Sanofi        Phase 2

7        APG-1252        Ascentage Pharma Group Inc.        Phase 2

8        Pacritinib        PSI CRO        Phase 3

9        FEDRATINIB        Celgene        Phase 3

10        NS-018        Nippon Shinyaku Co., Ltd.        Phase 2

11        NS-018        NS Pharma, Inc.        Phase 2

12        GB2064        Galecto Biotech AB        Phase 2

13        BMS-986158        Bristol-Myers Squibb        Phase 1

14        Ruxolitinib        Actuate Therapeutics Inc.        Phase 2

15        Imetelstat        Geron Corporation        Phase 3

16        TL-895        Telios Pharma, Inc.        Phase 2

17        Jaktinib Hydrochloride Tablets        Suzhou Zelgen Biopharmaceuticals Co.,Ltd        Phase 2

18        Navitoclax        AbbVie        Phase 3

19        APLIDIN (plitidepsin)        PharmaMar        Phase 2

20        rabbit anti-thymocyte globulin (ATG)        Otsuka America Pharmaceutical        Phase 2

21        Simtuzumab        Gilead Sciences        Phase 2

22        TP-3654        Sumitomo Dainippon Pharma Oncology, Inc        Phase 1

23        TBX-2400        Taiga Biotechnologies, Inc.        Phase 1

24        Pevonedistat        Takeda        Phase 1

25        Fostamatinib        Rigel Pharmaceuticals        Phase 2

26        MMB        Sierra Oncology, Inc.        Phase 2

27        IMG-7289        Imago BioSciences,Inc.        Phase 2

28        PU-H71        Samus Therapeutics, Inc.        Phase 1

29        Luitpold Azacitidine        American Regent, Inc.        Phase 1

30        Pacritinib        CTI BioPharma        Phase 2

31        CPI-0610        Constellation Pharmaceuticals        Phase 3

32        AZD1480        AstraZeneca        Phase 1

33        LNK01002        Lynk Pharmaceuticals Co., Ltd        Phase 1

34        CWP232291        JW Pharmaceutical        Phase 1

35        LY2784544        Eli Lilly and Company        Phase 1

36        SP-420        Abfero Pharmaceuticals, Inc        Phase 1

37        MDG1021 dose 1        Medigene AG        Phase 1

38        PRT543        Prelude Therapeutics        Phase 1

39        givinostat        Italfarmaco        Phase 2

40        rigosertib        Onconova Therapeutics, Inc.        Phase 2

41        AC220        Daiichi Sankyo, Inc.        Phase 1

42        Anagrelide CR        Galena Biopharma, Inc.        Phase 2

43        Lorvotuzumab Mertansine (IMGN901)        ImmunoGen, Inc.        Phase 2

44        TAS1553        Astex Pharmaceuticals, Inc.        Phase 1

45        Triciribine        Prescient Therapeutics, Ltd.        Phase 1

46        Ad26.Mos.HIV        Janssen Vaccines & Prevention B.V.        Phase 2"